Rebastinib is an investigational orally administered, potent and selective inhibitor of the TIE2 immunokinase. TIE2 is the receptor for angiopoietins, an important family of vascular and macrophage growth factors, and has an important role in regulating tumor angiogenesis, invasiveness, metastasis, and immunotolerance. TIE2 is expressed in pro-tumoral M2 macrophages known as “TIE2 expressing macrophages”, or TEMs. Rebastinib is in clinical development for the treatment of multiple solid tumors and in combination with chemotherapy.

Tumor TypeStatus
Solid Tumors:
Combo with Paclitaxel
Combo with Carboplatin
Phase 1 Study – Ongoing
Phase 1b/2 Study – Ongoing
Phase 1b/2 Study – Ongoing

Rebastinib in Solid Tumors:

Rebastinib is currently being evaluated in a Phase 1b/2 clinical study in combination with paclitaxel and in an investigator sponsored Phase 1b study. A second Phase 1b/2 clinical study of rebastinib in combination with carboplatin is planned. In preclinical testing rebastinib has shown activity as a single agent and when combined with paclitaxel, synergistic reductions in circulating tumor cells and ablations of distant metastases were observed. As a result, we believe rebastinib has the potential to be an important new therapy for cancer patients when combined with chemotherapy.

Further information on rebastinib is available as follows:

Press Release here »

In addition, further information regarding rebastinib and Deciphera’s pipeline is available in the most recent corporate presentation here »

On this page you may select links to content published by persons not affiliated with Deciphera. The views expressed in these materials are those of the author and do not reflect the views of Deciphera. Additionally, the information contained in these materials may not be current. Deciphera disavows any obligation to correct or to update the information contained in these materials.